| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10220525 | Journal of Thoracic Oncology | 2018 | 8 Pages |
Abstract
Single-agent nivolumab has meaningful clinical efficacy and a manageable safety profile in pre-treated patients with mesothelioma. PD-L1 expression does not predict for response in this population.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Josine MD, Vincent PhD, Jeltje F. PhD, Marion Zimmerman, Ferry MD, Erik MD, PhD, Kim MD, PhD, Robert MD, Laurel MS, Maria MD, Houke MD, PhD, Koen MD, PhD, Sjaak MD, PhD, Wieneke MD, Paul MD, PhD,